Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Microwave Ablation +/- Furmonertinib in Early-Stage NSCLC
NCT06969781Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Disease-Free Survival at 3 years. Planned start May 2025; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06969781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06969781.